- Medical School - Royal College of Surgeons (1980-1986)
- Residency - Children's Hospital of Denver (1996-1998), Pediatrics
- Fellowship - University of Colorado Health Sciences Center (1992-1996), Pediatric Hematology/oncology
- Residency - St. Vincents Hospital - Dublin Ireland (1987-1989), Internal Medicine
- Internship - Beaumont Hospital (1986-1987), General Surgery
Patrick Leavey, M.D.
- Pediatrics - Hematology-Oncology
Patrick Leavey graduated from the Royal College of Surgeons in Ireland in 1986. He spent 4 years in Ireland as a junior house officer (Internal Medicine and Pediatrics), 2 years at Princess Margaret Hospital in Perth, Western Australia as a pediatric registrar and then came to the US to do his pediatric hematology/oncology fellowship at The Children’s Hospital Denver and University of Colorado Health Sciences Center in 1992. Dr. Leavey worked in the lab of Daniel Ambruso, M.D. for 4 years on projects related to the influence of G-CSF on granulocyte function and the exploration and identification of a novel neutrophil cytosolic protein.
Dr. Leavey joined the pediatric faculty at UT Southwestern Medical Center in 1998 where he is currently a Professor of Pediatrics and a Pediatric Oncologist at Children’s Health, Children’s Medical Center Dallas and Plano.
During his years of training Dr. Leavey became a member of the Royal College of Physicians of Ireland, a Fellow of the Royal Australasian College of Physicians and a Diplomate of Child Health from the National University of Ireland. He submitted a thesis based on his work in the Ambruso laboratory and was granted a Doctorate in Medicine from the National University of Ireland. He is also subspecialty board certified in Pediatric Hematology/Oncology by the American Board of Pediatrics.
Currently Dr. Leavey holds several leadership positions both regionally and nationally. He is the Associate Medical Director for Clinical Affairs, for the Pauline Allen Gill Center for Cancer and Blood Disorders and the Director of the Musculoskeletal Tumors Program at Children's Health. Dr. Leavey is the Vice-President of the American Society of Pediatric Hematology/Oncology and a member of their Board of Trustees and Executive committee. He is the Secretary-Treasurer of the Council of Pediatric Subspecialties. At the Children’s Oncology Group (COG), Dr. Leavey is a member of the Bone Sarcoma Committee and the institutional principal investigator for UT Southwestern Medical Center. Dr. Leavey also serves on the advisory boards for the Children’s Cancer Fund and The Clayton Dabney Foundation.
Dr. Leavey hold several key positions in clinical and translational research. He is the Chair for the COG international study for newly diagnosed patients with non-metastatic Ewing Sarcoma (AEWS1031). He is the principal investigator for a Cancer Prevention Research Institute of Texas (CPRIT) funded study to develop a novel biomarker for osteosarcoma and he is the principal investigator for a Texas wide biospecimen study for childhood sarcoma also funded by CPRIT.
Dr. Leavey was included in D Magazine's Best Doctors list for 2018.
To schedule an appointment with Dr. Leavey at Children's Health, please call 844-4CHILDRENS or request an appointment online.
- Dallas County Medical Society and Texas Medical Association
- Connective Tissue Oncology Society
- Children's Oncology Group (2002)
- American Society of Pediatric Hematology/Oncology (2004)
- Society for Pediatric Research (2006)
- American Society of Clinical Oncology (2012)
- Best Pediatric Specialists, D Magazine, (2002, 2010, 2011, 2013, 2015, 2016)
- Achievement Award 2005, ’Gift of Giving Back Award’ first such award given by the Clayton Dabney Foundation for Kids with Cancer
- Elected to the Society for Pediatric Research 2006
- Medical Achievement Award 2008, Little Mo Award - awarded by Wipe out Kids Cancer
- Faculty Teaching Award 2009, UT Southwestern and Children's Medical Center
Histopathological Diagnosis for Viable and Non-viable Tumor Prediction for Osteosarcoma Using Convolutional Neural Network in Bioinformatics Research and Verlag
Mishra R, Daescu O, Leavey P, Rakheja D, Sengupta A. (2017), Springer
- Histopathological Diagnosis for Viable and Non-viable Tumor Prediction for Osteosarcoma Using Convolutional Neural Network in Bioinformatics Research and Verlag
Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation.
Armstrong AE, Walterhouse DO, Leavey PJ, Reichek J, Walz AL Pediatric blood & cancer 2018 Oct e27493
Viable and necrotic tumor assessment from whole slide images of osteosarcoma using machine-learning and deep-learning models.
Arunachalam HB, Mishra R, Daescu O, Cederberg K, Rakheja D, Sengupta A, Leonard D, Hallac R, Leavey P, PloS one 2019 14 4 e0210706
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.
Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N European journal of cancer (Oxford, England : 1990) 2019 Mar 109 36-50
Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.
Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD, British journal of cancer 2019 Apr 120 8 869
PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA, Garcia MR, Lardennois A, Leavey PJ, Maglic D, Fagnan A, Go JC, Roach J, Wang YD, Finkelstein D, Hatley ME Oncogene 2018 Jan
Hope as a Predictor of Anxiety and Depressive Symptoms Following Pediatric Cancer Diagnosis.
Germann JN, Leonard D, Heath CL, Stewart SM, Leavey PJ Journal of pediatric psychology 2017 Jul
Convolutional Neural Network for Histopathological Analysis of Osteosarcoma.
Mishra R, Daescu O, Leavey P, Rakheja D, Sengupta A Journal of computational biology : a journal of computational molecular cell biology 2017 Oct
The American Society of Pediatric Hematology/Oncology workforce assessment: Part 1-Current state of the workforce.
Hord J, Shah M, Badawy SM, Matthews D, Hilden J, Wayne AS, Salsberg E, Leavey PS Pediatric blood & cancer 2017 Oct
Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.
Shulman DS, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, London WB, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD British journal of cancer 2018 Aug
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.
Blumenthal GM, Bunn PA, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JMM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 Sep
Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group.
Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J, Brown K, Tarbell N, Bernstein ML, Granowetter L, Gebhardt M, Grier HE Pediatric blood & cancer 2008 Sep 51 3 334-8
The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma.
Ye D, Maitra A, Timmons CF, Leavey PJ, Ashfaq R, Ilaria RL Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 2003 Jun 25 6 459-66
In vivo treatment with granulocyte colony-stimulating factor does not delay apoptosis in human neutrophils by increasing the expression of the vacuolar proton ATPase.
Zimbelman J, Thurman G, Leavey PJ, Ellison MC, Ambruso DR Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2002 Jan 50 1 33-7
Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma.
Mantadakis E, Kim G, Reisch J, McHard K, Maale G, Leavey PJ, Timmons C Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 2001 Jun-Jul 23 5 286-9
Inappropriate long-term medication in patients admitted to a coronary care unit.
O'Sullivan JJ, Leavey P, Mulcahy R Journal of the Royal College of Physicians of London 1989 Oct 23 4 232-5
PAX genes in childhood oncogenesis: developmental biology gone awry?
Mahajan P, Leavey PJ, Galindo RL Oncogene 2014 Jul 0
KAI-1 expression in pediatric high-grade osteosarcoma.
Leavey PJ, Timmons C, Frawley W, Lombardi D, Ashfaq R Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2006 May-Jun 9 3 219-24
Important principles in Ewing sarcoma treatment.
Leavey PJ Pediatric blood & cancer 2014 Dec 61 12 2149-50
The effects of stem cell factor and granulocyte colony stimulating factor therapy on the activity of the neutrophil NADPH oxidase enzyme system.
Leavey PJ, Thurman G, Gonzalez-Aller C, Zerbe G, Ambruso DR Journal of investigative medicine : the official publication of the American Federation for Clinical Research 1998 Apr 46 4 121-6
Biomarker development in osteosarcoma-Is there no longer any utility to tumor necrosis?
Leavey PJ Pediatric blood & cancer 2016 Jun
Do pediatric hematology/oncology (PHO) fellows receive communication training?
File W, Bylund CL, Kesselheim J, Leonard D, Leavey P Pediatric blood & cancer 2014 Mar 61 3 502-6
Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma.
Dickens DS, Kozielski R, Leavey PJ, Timmons C, Cripe TP Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 2003 Apr 25 4 282-5
Variability in dose intensity of high-dose methotrexate for nonmetastatic osteosarcoma.
Leavey PJ, Mantadakis E, Maale G Pediatric hematology and oncology 2002 Oct-Nov 19 7 483-9
COMPUTER AIDED IMAGE SEGMENTATION AND CLASSIFICATION FOR VIABLE AND NON-VIABLE TUMOR IDENTIFICATION IN OSTEOSARCOMA.
Arunachalam HB, Mishra R, Armaselu B, Daescu O, Martinez M, Leavey P, Rakheja D, Cederberg K, Sengupta A, Ni'suilleabhain M Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 2016 22 195-206
IL-8 Predicts Pediatric Oncology Patients With Febrile Neutropenia at Low Risk for Bacteremia.
Cost CR, Stegner MM, Leonard D, Leavey P Journal of pediatric hematology/oncology 2013 Feb
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.
Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, Marina N, Leavey P, Gebhardt M, Healey J, Shamberger RC, Goorin A, Miser J, Meyer J, Arndt CA, Sailer S, Marcus K, Perlman E, Dickman P, Grier HE Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 May 27 15 2536-41
The prevalence and use of antidepressant medication in pediatric cancer patients.
Portteus A, Ahmad N, Tobey D, Leavey P Journal of child and adolescent psychopharmacology 2006 Aug 16 4 467-73
Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors.
Bowers DC, Aquino VM, Leavey PJ, Bash RO, Journeycake JM, Tomlinson G, Mulne AF, Haynes HJ, Winick NJ Pediatric blood & cancer 2004 Jan 42 1 93-8
A 29-kDa protein associated with p67phox expresses both peroxiredoxin and phospholipase A2 activity and enhances superoxide anion production by a cell-free system of NADPH oxidase activity.
Leavey PJ, Gonzalez-Aller C, Thurman G, Kleinberg M, Rinckel L, Ambruso DW, Freeman S, Kuypers FA, Ambruso DR The Journal of biological chemistry 2002 Nov 277 47 45181-7
Intra-operative radiation therapy in pediatric neuroblastoma.
Leavey PJ, Odom LF, Poole M, McNeely L, Tyson RW, Haase GM Medical and pediatric oncology 1997 Jun 28 6 424-8
Osteogenic sarcoma and Rothmund Thomson syndrome.
Varughese M, Leavey P, Smith P, Sneath R, Breatnach F, O'Meara A Journal of cancer research and clinical oncology 1992 118 5 389-90
Hoping is Coping: A Guiding Theoretical Framework for Promoting Coping and Adjustment Following Pediatric Cancer Diagnosis.
Germann JN, Leonard D, Stuenzi TJ, Pop RB, Stewart SM, Leavey PJ Journal of pediatric psychology 2015 Apr
Chemotherapy for Generalized Infantile Myofibromatosis With Visceral Involvement.
Wu SY, McCavit TL, Cederberg K, Galindo RL, Leavey PJ Journal of pediatric hematology/oncology 2014 Mar
How many physicians do we need? A benchmark for pediatric hematology/oncology.
Leavey PJ Pediatric blood & cancer 2012 Nov
Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney.
Roy A, Kumar V, Zorman B, Fang E, Haines KM, Doddapaneni H, Hampton OA, White S, Bavle AA, Patel NR, Eldin KW, John Hicks M, Rakheja D, Leavey PJ, Skapek SX, Amatruda JF, Nuchtern JG, Chintagumpala MM, Wheeler DA, Plon SE, Sumazin P, Parsons DW Nature communications 2015 6 8891
Humanism and professionalism education for pediatric hematology-oncology fellows: A model for pediatric subspecialty training.
Kesselheim JC, Atlas M, Adams D, Aygun B, Barfield R, Eisenman K, Fulbright J, Garvey K, Kersun L, Nageswara Rao A, Reilly A, Sharma M, Shereck E, Wang M, Watt T, Leavey P Pediatric blood & cancer 2014 Oct
Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a phase II window study.
Mantadakis E, Herrera L, Leavey PJ, Bash RO, Winick NJ, Kamen BA Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000 Jul 18 13 2576-81
Graduate medical education changes: yes we can or enough already?
Leavey PJ, Jubran RF Pediatric blood & cancer 2012 Dec 59 7 1168-72
Bone Scintigraphy in Osteosarcoma: A Single Institution Experience.
Powers JM, Cost C, Cederberg K, Leonard D, Leavey PJ Journal of pediatric hematology/oncology 2014 Jun
Predictive value of interleukin-5 and monocyte chemotactic protein-1 for bacteremia in children with febrile neutropenia.
Aquino VM, Cost C, Gomez A, Bowers DC, Ramilo O, Ahmad N, Winick N, Leavey PJ Journal of pediatric hematology/oncology 2012 Aug 34 6 e241-5
Ewing sarcoma: prognostic criteria, outcomes and future treatment.
Leavey PJ, Collier AB Expert review of anticancer therapy 2008 Apr 8 4 617-24
Skip metastasis in osteosarcoma.
Leavey PJ, Day MD, Booth T, Maale G Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 2003 Oct 25 10 806-8
Effective removal of methotrexate by high-flux hemodialysis.
Saland JM, Leavey PJ, Bash RO, Hansch E, Arbus GS, Quigley R Pediatric nephrology (Berlin, Germany) 2002 Oct 17 10 825-9
Brief report: successful therapy of a patient with infantile generalized myofibromatosis.
Day M, Edwards AO, Weinberg A, Leavey PJ Medical and pediatric oncology 2002 May 38 5 371-3
Functional characteristics of neutrophils collected and stored after administration of G-CSF.
Leavey PJ, Thurman G, Ambruso DR Transfusion 2000 Apr 40 4 414-9
In vivo treatment with granulocyte colony-stimulating factor results in divergent effects on neutrophil functions measured in vitro.
Leavey PJ, Sellins KS, Thurman G, Elzi D, Hiester A, Silliman CC, Zerbe G, Cohen JJ, Ambruso DR Blood 1998 Dec 92 11 4366-74
Langerhans cell histiocytosis--a 31 year review.
Leavey P, Varughese M, Breatnach F, O'Meara A Irish journal of medical science 1991 Sep 160 9 271-4
Extracorporeal membrane oxygenation (ECMO) initiation without intubation in two children with mediastinal malignancy.
Wickiser JE, Thompson M, Leavey PJ, Quinn CT, Garcia NM, Aquino VM Pediatric blood & cancer 2007 Oct 49 5 751-4
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KL, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PC, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MC, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS The Lancet. Oncology 2016 Aug
- Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation.
- Development of a novel biomarker for patients with Osteosarcoma
- Development of sophisticated genetic and clinically annotated data for patients with sarcoma in Texas
- Development of advances in therapy for patients with Ewing Sarcoma with an emphasis on protocol development for patients with newly diagnosed and recurrent Ewing Sarcoma